Denali Therapeutics (DNLI) Share-based Compensation (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Share-based Compensation data on file, last reported at $23.1 million in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 8.24% year-over-year to $23.1 million in Q1 2026; TTM through Mar 2026 was $97.6 million, a 2.63% decrease from a year earlier, with the FY2025 full-year figure at $99.6 million, down 3.15% from the prior year.
• Share-based Compensation for Q1 2026 stood at $23.1 million, down from $24.0 million in the prior quarter.
• Over the last five years, Share-based Compensation for DNLI reached as high as $28.1 million in Q1 2023 and fell as low as $23.1 million in Q1 2026.
• Historically, Share-based Compensation has averaged $25.5 million across 5 years, with a median of $25.2 million in 2025.
• Across the five-year window, Share-based Compensation gained 24.33% in 2022 and retreated 9.63% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $25.2 million in 2022, then increased by 3.18% to $26.0 million in 2023, then fell by 3.5% to $25.1 million in 2024, then fell by 4.49% to $24.0 million in 2025, then retreated by 3.61% to $23.1 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $23.1 million in Q1 2026, $24.0 million in Q4 2025, and $25.1 million in Q3 2025.